Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Dynamic prediction model and risk assessment chart for cardiovascular disease based on on-treatment blood pressure and baseline risk factors.

Teramukai S, Okuda Y, Miyazaki S, Kawamori R, Shirayama M, Teramoto T.

Hypertens Res. 2016 Feb;39(2):113-8. doi: 10.1038/hr.2015.120. Epub 2015 Nov 26.

2.

Lipid and blood pressure control for the prevention of cardiovascular disease in hypertensive patients: a subanalysis of the OMEGA study.

Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Sato Y, Okuda Y, Shirayama M.

J Atheroscler Thromb. 2015;22(1):62-75. doi: 10.5551/jat.25304. Epub 2014 Aug 29.

3.

Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.

Kario K, Uehara Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K, Komiya M, Shimada K.

Drugs R D. 2013 Mar;13(1):75-85. doi: 10.1007/s40268-013-0007-7.

4.

Inhibitory effects of azelnidipine tablets on morning hypertension.

Kario K, Sato Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K, Komiya M, Shimada K.

Drugs R D. 2013 Mar;13(1):63-73. doi: 10.1007/s40268-013-0006-8.

5.

Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study.

Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Shirayama M, Hiramatsu K, Kobayashi F; OMEGA Study Group.

Hypertens Res. 2012 Dec;35(12):1136-44. doi: 10.1038/hr.2012.93. Epub 2012 Jul 5. Erratum in: Hypertens Res. 2012 Dec;35(12):1203.

Supplemental Content

Loading ...
Support Center